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SHORT REPORT Open Access
The microbiome in pediatric cystic fibrosis
patients: the role of shared environment suggests
a window of intervention
Thomas H Hampton1, Deanna M Green2, Garry R Cutting3, Hilary G Morrison4, Mitchell L Sogin4, Alex H Gifford1,
Bruce A Stanton1 and George A O’Toole5*
Abstract
Background: Cystic fibrosis (CF) is caused by mutations in the CFTR gene that predispose the airway to infection.
Chronic infection by pathogens such as Pseudomonas aeruginosa leads to inflammation that gradually degrades
lung function, resulting in morbidity and early mortality. In a previous study of CF monozygotic twins, we
demonstrate that genetic modifiers significantly affect the establishment of persistent P. aeruginosa colonization in
CF. Recognizing that bacteria other than P. aeruginosa contribute to the CF microbiome and associated pathology,
we used deep sequencing of sputum from pediatric monozygotic twins and nontwin siblings with CF to
characterize pediatric bacterial communities and the role that genetics plays in their evolution.
Findings: We found that the microbial communities in sputum from pediatric patients living together were much
more alike than those from pediatric individuals living apart, regardless of whether samples were taken from
monozygous twins or from nontwin CF siblings living together, which we used as a proxy for dizygous twins. In
contrast, adult communities were comparatively monolithic and much less diverse than the microbiome of
pediatric patients.
Conclusion: Taken together, these data and other recent studies suggest that as patients age, the CF microbiome
becomes less diverse, more refractory to treatment and dominated by mucoid P. aeruginosa, as well as being
associated with accelerated pulmonary decline. Our studies show that the microbiome of pediatric patients is
susceptible to environmental influences, suggesting that interventions to preserve the community structure found
in young CF patients might be possible, perhaps slowing disease progression.
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Findings
Background
Cystic fibrosis (CF) is an inherited disease that affects over
70,000 people worldwide. It is caused by mutations in the
CF transmembrane conductance regulator (CFTR) gene.
Mutations in CFTR reduce airway surface liquid volume,
thereby reducing mucociliary clearance of bacterial patho-
gens that cause chronic inflammation [1]. Chronic infection
results in a decline of respiratory function and eventual
pulmonary failure, despite aggressive and repeated use of
antibiotics. Although the overall process of disease pro-
gression is unfortunately predictable, individual rates of
progression can vary tremendously, leaving some CF pa-
tients relatively healthy in their 30s and others in need
of lung transplants in their teens [2].
Pseudomonas aeruginosa is an opportunistic pathogen
found in approximately 80% of adult CF patients. It is the
presumed cause of most pulmonary exacerbations and
therefore the major target of antibiotic treatment in CF
patients [3]. Culture-dependent techniques applied to
the study of CF sputum are used to identify antibiotic-
resistant and susceptible strains of P. aeruginosa, as well
as Haemophilus influenzae, Burkholderia cepacia complex,
Staphylococcus aureus, Stenotrophomonas maltophilia and
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methicillin-resistant S. aureus, which also contribute to
the etiology of the CF phenotype [4]. Culture-independent
techniques (for example, 454 pyrosequencing of the bac-
terial 16S rRNA gene) can identify over 100 distinct gen-
era, including the commensal genera that provide the
microbial diversity found in children that gradually disap-
pears in adults. The results of studies such as those pub-
lished by Cox et al. [5] and Madan et al. [6] show that the
diversity of the CF microbiome peaks during childhood,
then falls during the second decade of life, when it is more
frequently dominated by P. aeruginosa. Goddard et al. [7]
showed that end-stage CF is associated with reduced
community diversity and domination by a few antibiotic-
resistant pathogens such as P. aeruginosa and B. cepacia
complex.
Investigators in a recent study of CF twins found that
pulmonary function among monozygous (MZ) twins is
more similar than that between dizygous (DZ) twin and
sibling pairs, regardless of whether they live together or
apart [8], suggesting that genetic modifiers play significant
roles in CF pulmonary function. In their study, genetic
factors accounted for 50% of pulmonary function vari-
ation, and, collectively, the remaining 50% were explained
by both stochastic and deterministic environmental influ-
ences. Specifically, unique environmental or stochastic
factors accounted for 36%, and shared environmental fac-
tors accounted for 14% of the remaining variation. Infec-
tion with environmental pathogens such as P. aeruginosa
contributes substantially to the progression of lung disease
in CF [9-11]; thus it is reasonable to expect that genetic
and/or nongenetic modifiers also impact infections. In-
deed, the timing of development of chronic P. aeruginosa
infection was more similar in MZ twins than in DZ twins
or other siblings, suggesting a strong genetic influence
of this trait [12].
In this study, we hypothesized that environmental fac-
tors substantially influence the development of the CF
pediatric microbiome, suggesting the possibility of ma-
nipulating these communities to a more healthful state.
We provide new insight into the mechanisms by which
shared environment contributes to infection status in CF
patients.
Methods
Patient consent and ethical approval
Adults who were 18 years of age or older with CF con-
firmed by genotype analysis were recruited from the
CF program at Dartmouth-Hitchcock Medical Center
(DHMC). They provided written informed consent as
approved by the DHMC Institutional Review Board.
Children ages 10 to 18 years old with CF confirmed by
genotype analysis were recruited from the CF program
at Johns Hopkins University School of Medicine. They
provided written informed consent as approved by the
Johns Hopkins University School Institutional Review
Board.
Data collection and statistical analysis
We analyzed the microbiome in the sputum from thirteen
clinically stable pediatric siblings from six families, of
which eight siblings were MZ twins and five were siblings
who served as proxies for DZ twins because they differed
in age by less than 3 years from the other child with CF
living in the same household. We compared the sputum
microbiomes of these pediatric patients (median age:
14 years) with each other and also to those of ten clinically
stable adults with CF chosen as randomly assigned con-
trols in an adult CF microbiome study (median age:
30 years) living apart [13]. The detailed demographics of
these samples can be found in Additional file 1: Tables S1
and S2. Pediatric samples were collected in accordance
with induced sputum protocols [14], and adult samples
were spontaneously produced as described by Gifford
et al. [13]. As CF twins are rare, our CF pediatric samples
were collected at seven different regional CF centers from
Texas to New York. Adult samples were collected at
DHMC. DNA isolated from the resulting 43 samples was
deep-sequenced, and unique genera were identified on the
basis of variable regions of the bacterial 16S ribosomal
gene as previously reported [15]. Three replicate samples
from adults were averaged to form ten representative sam-
ples. The sequence reads were similar between sets, with
an average of approximately 15,000 reads per pediatric
sample and about 12,000 reads per adult sample.
Bray-Curtis dissimilarity and Shannon Diversity Index
were measured using the ecodist [16] and vegan [17]
packages in R statistical software. Significant differences
between groups were established using analysis of vari-
ance with Tukey’s Honest Significant Difference posttest.
Tests producing a P value less than 0.05 were deemed
significant. The pediatric data sets have been deposited
in the Sequence Read Archive database (NCBI BioProject
PRJNA237382; National Center for Biotechnology Infor-
mation (NCBI), US National Library of Medicine,
Bethesda, MD, USA), and all data sets are also available
at http://vamps.mbl.edu/ (Visualization and Analysis of
Microbial Population Structures (VAMPS), Josephine Bay
Paul Center, Woods Hole, MA, USA) [18]. A summary of
the sequencing data read numbers and fractions can be
found in the supplemental data (Additional file 2).
Results
Figure 1A shows the fraction of reads and associated
bacterial genera for each of our 13 pediatric patients
from 6 different families. Notably, the microbiomes of
these pediatric patients is dominated by Streptococcus
spp., and P. aeruginosa accounted for a small fraction of
reads in any given sample. Comparing siblings living
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together to unrelated individuals reveals that the environ-
ment plays an important role in determining the compos-
ition of the microbiota. Both identical twins and siblings
living together (twins connected by a red dash in Figure 1A)
have very similar communities. For example, siblings in
families 1 and 6 are much more like each other than they
are to children from other families (Figure 1A). We also
compared the microbiomes of pediatric CF patients using
Bray-Curtis dissimilarity analysis (Figure 2A), which
confirmed that the siblings from the same family are
significantly more similar to each other than they are to
unrelated pediatric CF patients. Importantly, there was
no significant difference in relatedness of communities
between MZ twins versus nontwin siblings with CF
(a proxy for DZ twins) living together, despite the genetic
differences in these cohorts. This finding supports the hy-
pothesis that the environment may influence the airway
community.
Figure 1B shows the fraction of reads and associated
bacterial genera for ten unrelated adult patients. In con-
trast to the pediatric CF patient cohort, the microbiomes
of adult CF patients are dominated by P. aeruginosa,
with relatively little Streptococcus. In addition, a visual
inspection of the communities in the pediatric and adult
CF cohorts indicated that microbiome diversity is higher
in the pediatric cohort than in the adult cohort (com-
pare Figure 1A with Figure 1B). This observation was
confirmed by analysis of diversity using the Shannon
Diversity Index (Figure 2B) and is consistent with previ-
ous work showing that the biomes of infants with CF are
Figure 1 Analysis of microbial communities in pediatric and adult patients. (A) Nineteen genera accounted for 85% of the reads in sputum
collected from thirteen pediatric patients with cystic fibrosis (CF). Data are presented in a stacked bar chart of relative abundance as fractions of
total reads (y-axis) for the top 19 genera for each patient (x-axis). Families are numbered 1 to 6, and pairs of monozygous twins are connected
with a red dash. The color key indicating these 19 genera is shown at the bottom of the figure. Pediatric samples contain a large fraction of
genus Streptococcus, shown at the bottom of the bars in maroon. (B) Fifteen genera accounted for 85% of the reads in sputum collected from
ten adult patients with CF. Adult samples are often dominated by the genus Pseudomonas, shown in black. Burkholderia, shown in green, is
dominant in patient 8.
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dominated by Veillonella and Streptococcus. Diversity
rapidly increases in the first 21 months of life [6] and
peaks at around 11 years of age [21].
Conclusions
Our analysis of the sputum microbiomes in pediatric
CF patients supports the conclusion that environmental
factors—that is, all manner of nongenetic factors—play
an important role in determining the composition of the
CF microbiome and is in agreement with the results of
other studies of adults with CF that the environment is
an important determinant of the microbiomes found in
these patients [22]. We found that the microbiomes of
pediatric CF patients living together are much more
alike than those among individuals living apart, and, im-
portantly, there was no significant difference between af-
fected MZ twins and affected siblings living together.
These observations are consistent with the view that the
environment is an important factor in determining the
composition of the microbiome. Although it is possible
that a much larger sample size might resolve subtle dif-
ferences between affected siblings living together and
affected MZ twins living together, we saw no such differ-
ence in our small study. Nonetheless, we could easily see
differences between pediatric patients living in the same
house compared to those living apart. In any case, nu-
merous studies have identified an inverse relationship
between microbial diversity and lung function, as well
as inflammatory markers, in airway samples of adults
[23,24]. These observations suggest that novel thera-
peutic regimens that maintain diversity while reducing
total bacterial load may improve clinical outcomes and
prevent the development of a microbiome dominated by
mucoid P. aeruginosa that is tolerant to antibiotic ther-
apy. It is also possible that early exposure to microbes
and allergens permanently shapes the developing micro-
bial community in the lungs of CF patients. Such im-
printing could mean that patients who live together are
exposed to, and therefore colonized by, the same mi-
crobes. It would be interesting to know whether the
microbiota of these pediatric CF patients living together
would begin to diverge when they are removed from the
same home environment.
Importantly, the observation described herein that the
pediatric microbiome can be influenced by environment
suggests that the microbial communities in these patients
might be amenable to manipulation. We hypothesize that
early intervention to enhance or maintain the diversity of
the microbiota of young CF patients, perhaps by using
probiotics, holds promise for slowing disease progression
until a cure is found for this pernicious disease. Although
our data suggest that maintaining pediatric microbial di-
versity into adulthood may lead to better outcomes, effect-
ive strategies to maintain diversity will require a clearer
understanding of how microbial communities in the CF
pediatric airway evolve under the selective pressure of re-
peated antibiotic treatment.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article (and its additional files).
The data sets supporting the results of this article are
available in the SRA repository, http://www.ncbi.nlm.nih.
gov/sra/?term=SRP038106.
Figure 2 Relatedness and diversity of microbial communities. (A) Box-and-whisper plots of pairwise Bray-Curtis distances of the microbiomes
of pediatric cystic fibrosis (CF) patients as a function of genetic relatedness, showing significantly more distance between unrelated patients than
between related patients (P = 0.01), but no significant difference in relatedness between monozygotic (MZ) twins and nontwin siblings with CF
(a proxy for dizygotic (DZ) twins, labeled “DZ Sibling”). Boxes indicate median values as the center line of each box, which spans the interquartile
range. Whiskers demarcate 1.5× the interquartile range. These values reflect 70 pairwise comparisons among the samples from the ten unrelated
subjects, and four pairwise comparisons among samples from the five siblings. (B) Boxplots comparing Shannon Diversity Index in all children
with CF in this study and adults with CF reveal significantly lower diversity in adult versus the pediatric cohort (P = 0.001). Median Shannon Diversity
Index value from adult patients in the Tunney et al. study [19] is shown as the red line, and the median Shannon Diversity Index score in adult patients
reported by Zhao et al. [20] is shown as a blue line for comparison to our adult cohort. Whiskers denote 1.5 times the interquartile range defined by
the box. Open circles denote outlier values outside this range. Significance codes: ‘***’ P < 0.001; ‘**’ P < 0.01.
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Additional files
Additional file 1: Table S1 and Table S2. Two supplemental tables
summarizing the patient data for the patient cohorts that were the
subject of the study. CF, Cystic fibrosis; MaxFEV1, Maximum volume
exhaled at end of first second of forced expiration.
Additional file 2: Sequence data. Summary of demographic data of
each sample analyzed, as well the number and fraction of reads from
adult and pediatric samples.
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